Companies in #Anxiety Disorders

AtaiBeckley Inc. is a clinical-stage biopharmaceutical company developing treatments for mental health disorders, including psychedelic- and entactogen-based therapies for depression, anxiety, and opioid use disorder. The company was formed in November 2025 through the strategic combination of atai Life Sciences N.V. (founded 2018, publicly listed on Nasdaq since 2021) and Beckley Psytech Limited. Headquartered in New York, NY with primary research operations through its Berlin-based ATAI Life Sciences GmbH subsidiary, the company operates as the parent entity for both predecessor organizations' pipelines, with development programs spanning DMT-based therapies for treatment-resistant depression and a portfolio of additional psychedelic-derived compounds.

HMNC Brain Health is a Munich-based clinical-stage biopharmaceutical company developing personalized precision psychiatry treatments powered by AI and pharmacogenomics. Its pipeline includes two lead depression programs, one of which is an oral esketamine formulation being developed as a more convenient alternative to Johnson & Johnson's Spravato, and a separate novel mechanism in treatment-resistant depression. The company is leveraging companion-diagnostic and digital-phenotyping tools to stratify patients and improve response rates in major depressive disorder.